LP Therapeutics, Inc.
- UEI
- WJ5LCL2KWS81
- CAGE
- 6XK28
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase II, topic 326: development of novel therapeutic agents that target cancer stem cells | National Cancer Institute (NIH) | $1,489,000 | |
| Nanoparticles eradicating leukemia stem cells | National Cancer Institute (NIH) | $224,363 |
Quick answers
Is LP Therapeutics, Inc. registered in SAM.gov?
LP Therapeutics, Inc.'s SAM.gov registration expired on July 13, 2022.
What is LP Therapeutics, Inc.'s most recent federal award?
LP Therapeutics, Inc.'s most recent federal contract award is Sbir phase II, topic 326: development of novel therapeutic agents that target cancer stem cells (HHSN261201600041C), from National Cancer Institute (NIH), on September 19, 2016.
On GovTribe
See LP Therapeutics, Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors